U.S. Infectious Diseases Specialist Dr. Anthony Fauci on Thursday said his country is interested in involving Indian researchers in international clinical trials to test the safety and efficacy of the COVID-19 drug.
The National Institute of Allergy and Infectious Diseases has a long history of working with its partners in India, said Dr Fauci during an interview organized by the US-India Strategic and Partnership Forum.
He said that under the old Indo-US program, we will continue to work with India in the study of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). We also intend to involve Indian researchers in international clinical trials to test the safety and efficacy of various -COVID-19.
The relationship between the NIH and the Indian Department of Biotechnology and what the Indian Medical Research Council has assisted in producing important scientific and social achievements in the past.
“I hope they will continue to do so in the future. India’s contribution to global scientific knowledge is well-known. With strong support from the government and the private sector of biopharma, this information already provides solutions for the protection and care of COVID-19,” said Dr. Fauci.
India’s ambassador to the US Taranjit Singh Sandhu said as India intensified its production of the vaccine to address its own and global needs, it relied on United States support to ensure that its raw materials and supplies were well-received.
He said that Injecting the earth is their best way to deal with this wave, and it is the best way to accelerate economic recovery.
Recognizing that health cooperation in India and the US is not new, he said under the long-running Vaccine Action Program between the two nations, they developed a rotavirus vaccine, which causes severe diarrhea in children.
Indian companies have also produced more expensive HIV drugs for use in African countries, building on partnerships between US organizations and private companies, he said.
He said that Looking ahead, they need to invest in the future. Strengthening globalization will depend on how well we prepare for the coming epidemic. We need to work to expand our global programs in areas such as epidemiology, digital health and patient safety to deal with communicable, non-communicable diseases and improve modeling of infectious diseases, predicting and predicting.
Similarly, the provision of clinical technology, standards, and hospital experience, in the management of infectious diseases, particularly COVID-19, can add to the knowledge base, “said Mr Sandhu.
He said that he think it’s important to understand that when the US faced a crisis last year, it was India that continued to support the US in critical medicine. And India is facing its own challenges that we are on the rise.
Mr Sandhu said last year, as the epidemic hit, India reaffirmed the integrity of health care services, providing essential medicines in the US.
He said that this year, as the US backed India in the middle of the second wave, President Biden commemorated India’s assistance. Companies like Gilead and Merck who are here today are very important in providing vital medicines in India that have helped fight epidemics and saved countless lives.